Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.
The new data addressed the lack of studies examining melanoma incidence despite the existence of research examining increases in relative numbers of advanced melanomas during the pandemic.
Post-Doctoral Fellowship in Tumor Metastasis Research and Glycobiology in Full time, Postdoctoral, Life Science with Brigham and Women's Hospital (BWH). Apply Today.